Law360, New York (August 30, 2007, 12:00 AM EDT) -- Schering-Plough Corp. has won a boost in its battle to protect Clarinex, with a federal judge issuing a permanent injunction barring Indian generic drug maker Ranbaxy Laboratories Ltd. from manufacturing or selling a copycat version of the allergy medication until the life of the patent expires.
U.S. District Judge Mary L. Cooper handed down the consent judgment and order on Tuesday in the U.S. District Court for the District of New Jersey. Both Schering and Ranbaxy stipulated the terms of the injunction in April.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.